|
Marunick et al. [4] CS Patient 1
|
F
|
59
|
OST
|
STE + METX + AL (3)
|
|
Yarom et al. [6] RS
| | | | |
|
Patient 2
|
F
|
73
|
HTN
|
STE + METX + AL (7), infliximab
|
|
Patient 3
|
F
|
76
|
HTN + Arrhythmia + hypercholesterolemia
|
AL (1.5)
|
|
Malden & Pai [7] CS Patient 4
|
F
|
56
|
NO
|
STE + AL (1), leflunomide
|
|
Khamaisi et al. [8] RS Patient 5
|
F
|
73
|
DM
|
AL (> 0,5)
|
|
Marx et al. [9] CS
| | | | |
|
Patient6
|
F
|
NA
|
OST
|
STE + METX + AL (3.1)
|
|
Patient 7
|
F
|
NA
|
OST
|
STE + METX + AL (6.3)
|
|
Patient 8
|
F
|
NA
|
OST
|
STE + METX + AL (3.3)
|
|
Hamada [10] CR
| | | | |
|
Patient 9
|
F
|
68
|
OST
|
STE + RISE (4)
|
|
Barrow [11] CR
| | | | |
|
Patient 10
|
F
|
70
|
OST
|
STE + AL (< 3)
|
|
Junquera et al. [12] CS
| | | | |
|
Patient 12a/12b
|
M
|
73
|
NO
|
STE + METX + AL (3.8)
|
|
Mehanna et al. [13] CR
| | | | |
|
Patient 13
|
F
|
55
|
NO
|
STE + Leflunomide + oral BPs (1)
|
|
Favia et al. [14] CS
| | | | |
|
Patient 14a/14b
|
F
|
67
|
OST
|
STE + IBAN (1)
|
|
Kwon et al. [15] CR
| | | | |
|
Patient 15
|
F
|
71
|
OST + DM
|
STE + AL (3); OH
|
|
Sedghizadeh et al. [16] RS
| | | | |
|
Patient 16
|
F
|
63
|
OST + HTN
|
STE + chemotherapy + AL (3)
|
|
Lo et al. [17] RS
| | | | |
|
Patient 17
|
NA
|
NA
|
NO
|
oral BPs (4.8)
|
|
Patient 18
|
NA
|
NA
|
Hip Osteonecrosis
|
STE + oral BPs (2.6)
|
|
Shin et al. [18] CR
| | | | |
|
Patient 19
|
F
|
67
|
OST + HTN
|
AL (1) + HTN Drug
|
|
Park et al. [19] CS
| | | | |
|
Patient 20
|
F
|
68
|
OST
|
STE + AL (5)
|
|
Patient 21
|
F
|
69
|
OST + PLE + TB
|
STE + AL (10)
|
|
Patient 22
|
F
|
70
|
OST + HTN
|
STE + AL (6)
|
|
Manfredi et al. [20] CS
| | | | |
|
Patient 23
|
F
|
68
|
OST + DM + HTN
|
AL (4.25)
|
|
Patient 24
|
F
|
65
|
OST + HTN
|
AL (5)
|
|
Patient 25
|
F
|
79
|
OST
|
AL (4)
|
|
Patient 26
|
F
|
57
|
OST + DM + HTN
|
AL (> 3)
|
|
Conte-Neto et al. [21] CR
| | | | |
|
Patient 27
|
F
|
58
|
NO
|
AL (5)
|
|
Patient 28
|
F
|
68
|
OST
|
STE + METX + AL (7)
|
